USPatent applicationPatented

Method of moisturizing the skin by the topical application of Δ5-androstene-3β-ol-7,17 dione and metabolizable precursors thereof

Granted 4 Jun 2002 · 1 office action

Application· this page
9799313
filed 5 Mar 2001
Publication
Not published
not published
Patent
US 6,399,085
granted 4 Jun 2002

Life of the application

15 dated events
⤢ drag to zoom20022004200620082010201220142016201820202022ProsecutionOwnershipTerm & fees
ProsecutionOwnershipTerm & feeshover for detail · click to open

Abstract

Human skin can be moisturized by the administration of 5-androstene-3-ol-7,17 dione and metabolizable precursors thereof, such as 5-androstene-3-acetoxy-7,17 dione.

Description

4 parts
›FIELD OF THE INVENTION

This invention relates to skin moisturizing methods and compositions.

›BACKGROUND

One of the primary functions of the human skin is to protect the body from adverse environmental factors. Unfortunately, these same environmental factors tend to dry and flake the skin. The skin derives some protection from environmental conditions by a complex lipid layer that covers the skin surface. This natural lipid layer slows down the absorption of foreign substances and confers water-shedding properties.

Dry skin affects most people at some point in their lives, particularly the older and light-skinned. Usually, it occurs on hands and legs and, to some extent, the face. Even though it is known that loss of the skin's moisturizer leads to flaking, chapping, or other irritation of body surfaces, no one knows precisely how to define the problem, not even dermatologists and cosmetologists.

A variety of conditions tends to dry the skin and alter the normal properties and functions of the skin, including the ability to function as a protective barrier. Damage may result from such conditions as low humidity, wind, cold, heat, and exposure to ultra violet rays, and contact with harsh chemicals such as soaps, detergents, and solvents. Protection against such damage can be obtained by applying various compounds such as oils, petrolatum, and a host of commercially available moisturizing creams and lotions. Scientific studies seem to indicate that only lanolin and petroleum jelly (petrolatum) can provide significant long-term improvements. However, undesired side effects are often associated with prolonged use of such compounds, including acne and other inflammations thought to be produced by clogged pores.

Accordingly, a need exists for a composition effective for achieving long-term moisturizing of human skin without the undesired side effects associated with prolonged application of lanolin and/or petrolatum.

›SUMMARY OF THE INVENTION

The invention is directed to the administration of Δ5-androstene-3β-ol-7,17 dione and metabolizable precursors thereof, such as Δ5-androstene-3β-acetoxy-7,17 dione, to moisturize human skin in need of moisturizing. These steroids are also effective for improving skin softness, flexibility, plasticity, and elasticity.

›DETAILED DESCRIPTION OF THE INVENTION INCLUDING A BEST MODE

Human skin can be moisturized by the administration of Δ5-androstene-3β-ol-7,17 dione and metabolizable precursors thereof, such as Δ5-androstene-3β-acetoxy-7,17 dione, to the skin.

The Compound

The steroid Δ5-androstene-3β-ol-7,17 dione is a derivative of dehydroepiandrosterone (DHEA) which does not appreciably stimulate, increase or otherwise enhance the production of sex hormones. The steroid is commercially available from a number of sources including Steraloids, Inc. of Wilton, N.H. A number of procedures are available for synthesizing Δ5-androstene-3β-ol-7,17 dione from DHEA, with one such procedure described in U.S. Pat. No. 5,296,481.

Precursors of Δ5-androstene-3β-ol-7,17 dione may also be usefully employed to moisturize human skin. Such precursors are readily metabolized in vivo to the active Δ5-androstene-3β-ol-7,17 dione. One example of such a metabolizable precursor is the commercially available Δ5-androstene-3β-acetyl-7,17 dione. The 3β-acetyl group is hydrolyzed in vivo by esterases located in the blood and various tissue to produce the active Δ5-androstene-3β-ol-7,17 dione, and is believed to be less susceptible to oxidation during the manufacturing process than the hydroxy group found on the active Δ5-androstene-3β-ol-7,17 dione. The steroid is commercially available from Humanetics Corporation of Chanhassen, Minn. under the trademark “7-KETO.”

Other metabolizable precursors include Δ5-androstene-3β, 17β-diol-7-one, Δ5-androstene-3β, 7α-diol-17-one, Δ5-androstene-3β, 7β-diol-17-one and the corresponding acetyl esters of these steroids.

Administration

The steroid can be conveniently administered by incorporating the steroid into a lipophilic carrier to form a cream, lotion, ointment, gel, pomade, or balm (hereinafter collectively referenced as composition) and topically applying the composition to the area in need of moisturizing.

The composition may be applied over the entire body or selected areas. Areas of particular interest, which can benefit from the moisturizing effect of the steroid include the hands, elbows, feet, knees, and face.

The composition can include from about 0.2 to 20-wt % steroid, preferably about 0.5 to 10-wt %, steroid. A concentration of less than about 0.2-wt % steroid tends to require the application of an uncomfortably large amount of the composition to achieve the desired long term moisturizing effect while a concentration of greater than about 20-wt % steroid tends to increase the cost of the composition without a corresponding increase in the extent or duration of the moisturizing effect.

The composition can contain those adjuvants or additives which are commonly included in such compositions, such as hydrophilic or lipophilic gelling agents, preservatives, antioxidants, solvents, fragrances, fillers, screening agents, and colorants. The amounts of these various adjuvants or additives are those conventionally used in the cosmetics and dermatological fields, which are commonly from about 0.01 to about 20-wt % of the composition.

The composition can be beneficially employed by topically applying the steroid to the skin on a daily basis, such as after bathing or just prior to bedtime.

Claims as granted

9 claims

Log in to read the claims of this application.

Log in to unlock

Classifications

5 codes
IPC · International Patent Classification
Section A — Human necessities
  • A61K8/63
  • A61Q19/00
USPC · US Patent Classification
424/401514/177514/178

Claim changes

Soon
Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this application are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoomApr 2001Jul 2001Oct 2001Jan 2002Apr 2002Jul 2002USPTOApplicantNon-final rejectionResponse after non-finalNotice of allowance
USPTOApplicanthover for detail · click to open
Pendency
1.2 y
456 days filing → grant
Office actions
1
non-final + final
Responses
2
no RCE
Examiner
Michael G. Hartley
art unit 1617 · TC 1600
Citations: 33 back · 1 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Log in to unlock

Documents

Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.

Log in to unlock

Chain of title

⤢ drag to zoom20022004200620082010201220142016201820202022Owner 1Owner 2liens, releases & corrections
TitleLienReleasehover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.

Log in to unlock